Treatment resistance of rheumatoid arthritis relates to infection of periodontal pathogenic bacteria: a case–control cross-sectional study

Kazu Takeuchi-Hatanaka1, Yoshinobu Koyama2, Kentaro Okamoto3, Kyosuke Sakaida4, Tadashi Yamamoto3 & Shogo Takashiba3*

Recent studies have shown that periodontitis is associated with rheumatoid arthritis (RA) and periodontal bacteria, such as Aggregatibacter actinomycetemcomitans (Aa) and Porphyromonas gingivalis (Pg) are involved in the pathogenesis of RA via citrullinated proteins. Smoking has also been shown to be involved in the pathogenesis of RA; however, the extent of this involvement is still poorly understood. In addition, RA and polymyalgia rheumatica (PMR) are sometimes difficult to differentiate; however, the relationship between PMR and the factors from smoking and periodontal bacteria is unclear. The aim of this study was to clarify the relationship between periodontal pathogenic bacterial infections and smoking in patients with RA or PMR. This case–control study included 142 patients with untreated RA or PMR. This study evaluated the serum antibody titers against periodontal pathogenic bacterial antigens and an anti-citrullinated peptide antibody (ACPA). In patients with RA, the relationship between antibody titers and disease activity of RA and response after 3 months of treatment was also investigated. Additionally, the effects of smoking were evaluated. Although there was no significant difference in serum antibody titer against periodontal pathogenic bacteria between the ACPA-positive RA group and the ACPA-negative PMR group, we found an association between the elevated antibody titer against Pg and the degree of ACPA value, especially between negative group and high-value positive group (≥ 100 U/mL). The antibody titers against Aa and Pg did not differ depending on disease activity score 28 (DAS28) at baseline; however, patients with high antibody titers had poor RA therapeutic response as judged by DAS28 after 3 months. We could not find any association between smoking and any of these parameters. Periodontal pathogenic bacteria, especially Pg, are associated with elevated ACPA levels. Our findings suggest that Pg and Aa infections interfere with the therapeutic response of RA.

Abbreviations

Aa  Aggregatibacter actinomycetemcomitans
ACPA  Anti-citrullinated peptide antibody
ACR  American College of Rheumatology
CRP  C-reactive protein
DAS28  Disease activity score 28
ELISA  Enzyme-linked immunosorbent assay
ESR  Erythrocyte sedimentation rate
EULAR  European Alliance of Associations for Rheumatology
IgG  Immunoglobulin G

1Department of Periodontics and Endodontics, Okayama University Hospital, Okayama, Japan. 2Center for Autoimmune Diseases, Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan. 3Department of Pathophysiology-Periodontal Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8525, Japan. *email: stakash@okayama-u.ac.jp
Pf, Porphyromonas gingivalis
FMR, Polymyalgia rheumatica
RA, Rheumatoid arthritis
RF, Rheumatoid factor
SD, Standard deviation
SE, Standard error

Rheumatoid arthritis (RA) and periodontitis are both chronic inflammatory diseases associated with bone destruction, release of inflammatory cytokines, and osteoclastic activity, and smoking is a common risk factor for both diseases. Several previous studies have reported a high prevalence of mutuality between RA patients and periodontitis patients. A meta-analysis found that patients with RA had an approximately 13% greater risk of developing periodontitis than healthy controls, ranging from 4 to 23% (relative risk: 1.13; 95% confidence interval [CI]: 1.04, 1.23; p = 0.006). Periodontitis is a disease that is initially caused by infection with periodontal pathogenic bacteria, and measurement of serum IgG antibody titers against these bacteria is one of the periodontal examinations. For rheumatologists, who have difficulty obtaining clinical data of periodontitis themselves, the use of blood test is an easy and effective means of ascertaining the extent of periodontitis without oral examination.

Porphyromonas gingivalis (Pg), a periodontal pathogenic bacterium, is the only bacteria in the oral cavity with the enzyme that converts arginine to citrulline. It has been proposed that when infected with Pg, a periodontal tissue protein is citrullinated by this enzyme and the resultant anti-citrullinated protein antibody (ACPA) forms an immune complex with citrullinated proteins in the joints, thereby inducing arthritis. ACPA is a main marker of RA with a sensitivity of 70% and specificity of 90%. Previous studies reported that serum immunoglobulin G (IgG) antibody titer to Pg was significantly higher in patients with RA than that in those without RA. A series of studies on the onset and progression mechanism of periodontitis and RA showed that the serum antibody reactions to arginine converting enzyme of Pg may reflect reactivity to anti-rheumatic drugs. Aggregatibacter actinomycetemcomitans (Aa), a periodontal pathogenic bacterium, has an influence on activation of citrullinating enzyme by producing an exotoxin in the form of a leukotoxin. However, it was reported that the serum antibody titer to Aa in patients with RA were significantly lower than those in controls. In addition, metagenomic sequencing and polymerase chain reaction analyses in subgingival plaque have not revealed a significant association between the presence of Aa and RA.

RA has some genetic background, and in particular, the association of the HLA-DRB1 allele, which contains a specific amino acid motif called the shared epitope (SE), with disease susceptibility and severity of RA has received considerable attention. It was later reported that the association between RA and SE is more pronounced in the ACPA-positive group than in the ACPA-negative group. In addition, there are seemingly contrasting genetic backgrounds and different underlying etiologies in patients with ACPA-positive and -negative RA. The presence and levels of ACPA have been reported to be associated with periodontal conditions in patients with RA. As a comparative disease of RA, we focus on polymyalgia rheumatica (PMR), a collagen disease that is often difficult to distinguish from RA. PMR is common in the elderly and is associated with inflammatory reactions, such as increased erythrocyte sedimentation rate (ESR) and elevated C-reactive protein (CRP) levels; however, rheumatoid factor (RF) and ACPA are usually absent. To date, no studies have reported the relationship between periodontitis and PMR. The originality of this study lies in the comparison of IgG antibody titers against periodontal bacteria between the patients suffering from ACPA-positive RA and those suffering from ACPA-negative PMR, analogous disease of RA as controls. RA activity is known to affect periodontitis. Rodriguez-Lozano et al. reported a significant association between the severity of periodontitis and RA disease activity. Another report showed that periodontitis affects the therapeutic response to biologics used in the treatment of RA. Therefore, we investigated the disease activity and therapeutic response of RA and the antibody titer against periodontal pathogenic bacterial antigens in patients with RA. The elucidation of the relationship between periodontitis and RA through the origin, disease activity, and therapeutic response will contribute to future medical advances.

The aim of this study was to clarify the relationship between periodontal pathogenic bacterial infections and smoking in patients with RA or PMR.

Methods
Study population. Japanese patients with RA or PMR who first visited the Japan Red Cross Okayama Hospital between March 2012 and February 2018 without any treatment history were all enrolled in this study. Their sera were provided by the "sample bank" of the hospital. RA was diagnosed based on the results of 2010 American College of Rheumatology or the European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria. PMR was diagnosed based on the results of 2012 EULAR/ACR provisional classification criteria.

Study design. This was an observational, case–control cross-sectional study of patients with RA or PMR. The titers of ACPA were measured using Architect Anti-CCP (Abbott Japan LLC, Tokyo). The standard criteria for ACPA negative and positive is 4.5 U/mL, which is the standard of most laboratories employed in Japan. The criteria for positive and high positive are based on Ref. ACPA is a disease activity score 28 (DAS28-CRP and DAS28-ESR) was calculated using the DAS-score website (http://www.das-score.nl/). Based on the amount of improvement in DAS28 after 3 months, RA therapeutic response was classified according to the EULAR criteria as good, moderate, or no response. To simplify the result of therapeutic response, we also categorized patients into two groups based on the DAS ratio (DAS ratio = DAS28-ESR or CRP at 3 months/DAS28-ESR or CRP at 3 months).
baseline: good responders < 0.75 and poor responders ≥ 0.75)\textsuperscript{33}. In addition, smoking status was questioned and classified into three categories: current, former, and never.

Patients were classified according to the disease, RA or PMR (Supplemental Fig. S1), and the degree of ACPA titers (Supplemental Fig. S2). Furthermore, patients with RA were classified according to DAS28-CRP or DAS28-ESR (Supplemental Fig. S3). In addition, they were classified according to the therapeutic response, as determined by the changes in DAS28 after 3 months (Fig. 1). The exclusion criteria were first to exclude samples with missing values for each of them. After that, the flowchart is as shown in Fig. 1 and supplemental Figs. S1–S3. The patients’ serum IgG titers against periodontal pathogenic bacterial antigens were analyzed.

**Measurement of serum IgG titers against periodontal pathogenic bacterial antigens.** Serum IgG titers against the crude extracts of sonicated periodontal bacteria were measured using enzyme-linked immunosorbent assay (ELISA), as previously described\textsuperscript{34,35}. All patients’ sera were obtained at just before treatment after diagnosis. Sonic extracts of periodontal bacteria, including *Aa* Y4, *Aa* ATCC29523, *Aa* SUNY67, *Pg*...
ESR and CRP) and poor response (≥ 0.75: 47 by DAS28-ESR and 41 by DAS28-CRP) (Fig. 1).

were also classified according to the DAS ratio (= DAS at 3 M / DAS at baseline) as good (< 0.75: 37 by DAS28-ESR and 19 by DAS28-CRP), and no response (36 by DAS28-ESR and 35 by DAS28-CRP). They with RA grouped by EULAR response criteria were good (23 by DAS28-ESR and 30 by DAS28-CRP), moderate (25 by DAS28-ESR and 19 by DAS28-CRP), and no response (36 by DAS28-ESR and 35 by DAS28-CRP). Therapeutic responses in patients with RA were analyzed based on disease activity (Supplemental Fig. S3). The DAS28-CRP level was ≥ 2.3 in 81 samples and was compared between three groups, 2.6–3.2; 3.2–5.1; and ≥ 5.1. FDC381, and Pg SU63, were used as antigens for ELISA. In this study, the average antibody titers against these three strains of Aa and two strains of Pg were used. Antibody titer was defined using the following formula: titer = (ELISA unit of the patient – mean of the healthy controls) / 2 standard deviations [SD] of the healthy controls. The healthy controls were 10 generally healthy adults without periodontitis, and their pooled-sera were used for drawing calibration curve.

### Statistical analysis.
To understand whether age and smoking affect RA parameters and the degree of infection with periodontal bacteria, their correlation coefficients were examined. The serum IgG antibody titers of each group were compared using Student's t-test or one-way analysis of variance and post-hoc analysis (Bonferroni test). In each comparison, smoking status was examined using Fisher's exact test or Pearson's chi-square test. The relationship between therapeutic response and periodontal bacterial infection and smoking was analyzed using Pearson's chi-square test, as shown in the Marimekko Chart. In order to evaluate the relationship between therapeutic response of RA (objective variable) and periodontal bacterial infection (explanatory variables; IgG titers against Pg and Aa) with adjusted factors (age, sex, ACPA, and smoking), a multivariate analysis was performed using logistic regression models. In these analyses, statistical significance was set at P < 0.05.

The statistical software JMP version 9.0.2 (SAS Institute Inc., Cary, NC, USA) and NCSS version 2021 (JUCA, Inc., CA) were used to analyze the data.

### Ethics approval and consent to participate.
We confirm that all methods employed in this study were carried out in accordance with relevant guidelines and regulations (Declaration of Helsinki). This study protocol was approved by the Ethics Committee of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences (acceptance number 1709-040). Written informed consent was obtained from all study participants for using their samples from the “sample bank” of the Japan Red Cross Okayama Hospital.

### Consent for publication.
In this manuscript, individual patient data are not presented.

### Results

#### Target sample of the study.
One hundred forty-two samples (from 47 men and 95 women, average age 64.9 ± 15.1 years) were collected for this study. In the characteristics of all patients, median ACPA, ESR, CRP, and RF values were far above the normal values (Table 1). First, serum IgG antibody titers against periodontal bacteria in patients with PMR and RA were measured (Supplemental Fig. S1). Thirty-eight samples of the PMR group were ACPA negative and 82 samples of the RA group were ACPA positive. Next, antibody titers were analyzed based on the degree of ACPA titers (Supplemental Fig. S2). The ACPA level was < 4.5 U/mL in 53 samples, ≥ 4.5 U/mL or < 100 U/mL in 29 samples, and ≥ 100 U/mL in 58 samples. Furthermore, antibody titers of patients with RA were analyzed based on disease activity (Supplemental Fig. S3). The DAS28-CRP level was ≥ 2.3 in 81 samples and was compared between three groups, 2.3–2.7; 2.7–4.1; and ≥ 4.1. The DAS28-ESR value was ≥ 2.6 in 86 samples and was compared between three groups, 2.6–3.2; 3.2–5.1; and ≥ 5.1. Therapeutic responses in patients with RA grouped by EULAR response criteria were good (23 by DAS28-ESR and 30 by DAS28-CRP), moderate (25 by DAS28-ESR and 19 by DAS28-CRP), and no response (36 by DAS28-ESR and 35 by DAS28-CRP). They were also classified according to the DAS ratio (= DAS at 3 M / DAS at baseline) as good (< 0.75: 37 by DAS28-ESR and 43 by DAS28-CRP) and poor response (≥ 0.75: 47 by DAS28-ESR and 41 by DAS28-CRP) (Fig. 1).

#### Possible influence of factors, such as age and smoking, on the pathophysiology of RA.
Patients’ age was negatively correlated with ACPA levels and positively correlated with DAS28 but not with periodontal bacterial infection (Supplemental Table S1). Smoking status was not correlated with either RA or periodontal disease parameters (Supplemental Table S2 and Supplemental Fig. S4). In addition, there was no difference in history of smoking between the groups divided by disease (PMR or RA), degree of ACPA titers, and disease activity (Tables 2, 3, 4). There were also no significant differences between smoking and therapeutic responses; however, patients who had never smoked tended to have a better response to RA treatment (Fig. 2).

### Table 1. Patient characteristics and clinical parameters. Data represent numbers (percentages), mean (SD), or median (P25, P75, Ref.)

| Factor                      | Value                                                                 |
|-----------------------------|-----------------------------------------------------------------------|
| Sex                         | Female 95 (67%), Male 47 (33%)                                         |
| Mean Age (SD)               | 64.9 years (15.1)                                                     |
| Smoking                     | Current 16 (11%), Former 36 (25%), Never 90 (63%)                     |
| Median ACPA (P25, P75, Ref.)| 91.7 U/mL (2.2; 401; 4.5)                                             |
| Median ESR (P25, P75, Ref.)  | 51 mm/h (27; 80; 20)                                                  |
| Median CRP (P25, P75, Ref.)  | 1.48 mg/dL (0.46; 4.56; 0.3)                                          |
| Median RF titers (P25, P75, Ref.) | 80 IU/mL (28; 176; 15)                                      |
Serum IgG titers against periodontal pathogenic bacterial antigens.

The averages and standard errors of serum IgG antibody titers in patients with PMR and RA are shown in Table 2. There were no significant differences in antibody titers between the PMR and RA groups. Effect of smoking was tested using Fisher's exact test for "a" and Pearson's chi-square test for "b". "Comparison between each value (3 × 2 Fisher's exact test). Comparison between "current + former" vs "never" (2 × 2 Pearson's chi-square test).

Table 2. Serum IgG antibody titers of patients with PMR and RA. Data are expressed as means ± SE (median). Aa Aggregatibacter actinomycetemcomitans, IgG immunoglobulin G, Pg Porphyromonas gingivalis, PMR polymyalgia rheumatic, RA rheumatoid arthritis, SE standard error. There were no significant differences in antibody titers between the PMR and RA groups. Effect of smoking was tested using Fisher's exact test for "a" and Pearson's chi-square test for "b". "Comparison between each value (3 × 2 Fisher's exact test). Comparison between "current + former" vs "never" (2 × 2 Pearson's chi-square test).

|                | PMR (n = 38) | RA (n = 82) | P-value |
|----------------|-------------|-------------|---------|
| Smoking        |             |             |         |
| Current        | 3 (7.9%)    | 12 (14.6%)  | 0.4811  |
| Former         | 7 (18.4%)   | 18 (22.0%)  |         |
| Never          | 28 (73.7%)  | 52 (63.4%)  |         |
| Aa titer       | 0.98 ± 0.27 (0.93) | 1.11 ± 0.19 (0.79) | 0.6930  |
| Pg titer       | 0.62 ± 0.60 (0.42) | 1.63 ± 0.40 (0.38) | 0.1635  |

Table 3. Serum IgG antibody titers based on the degree of ACPA titers. Data are expressed as means ± SE. Aa Aggregatibacter actinomycetemcomitans, ACPA anti-citrullinated peptide antibody, IgG immunoglobulin G, Pg Porphyromonas gingivalis, SE standard error. The antibody titers against Aa did not differ significantly depending on the degree of ACPA titers, but the antibody titer against Pg showed a significantly high value as the degree of ACPA titers (P-value = 0.0491: one-way analysis of variance, *P-value < 0.05). There was also a significant difference in Pg when comparing the negative group and the high-value ACPA positive group (P = 0.0368: Bonferroni test, *P-value < 0.05). Effect of smoking was tested using Fisher's exact test for "a" and Pearson's chi-square test for "b". Comparison between each value (3 × 3 Fisher's exact test). Comparison between "current + former" vs "never" (2 × 3 Pearson's chi-square test).

|                | Negative ACPA < 4.5 (n = 53) | Positive 4.5 ≤ ACPA < 100 (n = 29) | High-value positive ACPA ≥ 100 (n = 58) | P-value |
|----------------|------------------------------|-------------------------------------|----------------------------------------|---------|
| Smoking        |                              |                                     |                                        |         |
| Current        | 3 (5.7 %)                    | 3 (10.3 %)                          | 9 (15.5 %)                             |         |
| Former         | 15 (28.3 %)                  | 7 (24.1 %)                          | 14 (24.1 %)                            | 0.5935  |
| Never          | 35 (66.0 %)                  | 19 (65.5 %)                         | 35 (60.3 %)                            | (0.8300) |
| Aa titer       | 0.86 ± 0.22 (1.08 ± 0.30)    | 1.11 ± 0.21                         | 0.7113                                 |
| Pg titer       | 0.54 ± 0.48 (0.87 ± 0.65)    | 2.12 ± 0.46                         | 0.0491*                                |

Serum IgG titers against periodontal pathogenic bacterial antigens. The averages and standard errors of serum IgG antibody titers in patients with PMR and RA are shown in Table 2. There were no significant differences in antibody titers between the PMR and RA groups. Serum IgG antibody titers against Aa were not significantly different according to the degree of ACPA titers; however, serum IgG titers against Pg were significantly higher in the group with a higher degree of ACPA titers (Table 3, p = 0.0491). There was also a significant difference in Pg when comparing the negative group and the high-value ACPA positive group (P = 0.0368: Bonferroni test, *P-value < 0.05). Effect of smoking was tested using Fisher's exact test for "a" and Pearson's chi-square test for "b". Comparison between each value (3 × 3 Fisher's exact test). Comparison between "current + former" vs "never" (2 × 3 Pearson's chi-square test).

The relationship between serum IgG titer against periodontal bacteria and therapeutic response is shown in Fig. 3. There were no significant differences between IgG antibody titers and therapeutic responses defined by the EULAR response criteria (Fig. 3AB). However, there were significant differences between IgG antibody titers and therapeutic responses defined by the DAS ratio at 0.75 calculated using DAS28-ESR (Fig. 3C, p = 0.0301) and DAS28-CRP (Fig. 3D, p = 0.0049). Pg titer was associated with therapeutic response (DAS28-CRP ratio of 0.75) with an odds ratio (95% CI) of 2.85 (1.12–7.27) and p-value of 0.0284. Aa titer was not significantly associated with an odds ratio (95% CI) of 1.78 (0.740–4.27), with p-value of 0.198.

Discussion

In the present study, serum antibody titers against periodontal bacteria related to citrullination were compared by the degree of ACPA titers among patients with RA and PMR. The antibody titer against Pg was significantly high in the ACPA-positive patients (Table 3). Although there was no statistically significant difference, the average antibody titer against Pg was higher in patients with RA than in those with PMR (Table 2). These results are
consistent with the results of a previous report\textsuperscript{15,37}, which compared patients with and without RA. Another study reported that ACPA-positive individuals had increased relative abundance of \( Pg \) but not \( Aa \), suggesting that they may be targets for preventive intervention for RA\textsuperscript{38}. Therefore, \( Pg \) infection may be considered to be associated with ACPA-positive RA. In addition, the severity of periodontitis has been reported to be significantly associated with RA activity\textsuperscript{39,40}. Serum antibody titers against bacteria correlate with severity of periodontitis\textsuperscript{40,41}. Because ACPA is related with PG enzyme called peptidylarginine deiminase\textsuperscript{42}, we focused on the infection severity of both \( Aa \) and \( Pg \) in this study.

To analyze the effect of smoking on antibody titers, smoking status was classified into current, former, and never smokers. As shown in Table 4, smoking status significantly affected antibody titers, with current smokers having significantly lower antibody titers than never smokers. This result is consistent with previous studies\textsuperscript{43,44}, which reported that smoking was associated with decreased antibody titers against periodontal bacteria. However, in our study, smoking was not significantly associated with RA activity, but the IgG antibody titers against \( Aa \) were significantly lower in current smokers than in never smokers.

To further investigate the relationship between smoking and RA activity, we performed logistic regression analysis using DAS28 scores as a predictor variable. The results showed that smoking status was a significant predictor of RA activity, with current smokers having a higher risk of poor therapeutic response than never smokers. This result is consistent with previous studies\textsuperscript{45,46}, which reported that smoking is a major environmental risk factor for RA.

Table 4. Serum IgG antibody titers by disease activity. Data are expressed as means ± SE. \( Aa \) Aggregatibacter actinomycetemcomitans, \( Pg \) Porphyromonas gingivalis, DAS28 disease activity score 28, ESR erythrocyte sedimentation rate, IgG immunoglobulin G.

\begin{table}[h]
\centering
\begin{tabular}{|l|c|c|c|c|}
\hline
\textbf{DAS28-ESR} & \textbf{Low activity} & \textbf{Moderate activity} & \textbf{High activity} & \textbf{P-value} \\
\hline
\textbf{2.6 ≤ DAS28 < 3.2} (n = 10) & & & & \\
\hline
\textbf{Current} & 1 (10.0%) & 5 (11.1%) & 6 (19.4%) & 0.3372 \textsuperscript{a} (0.1339) \\
\textbf{Former} & 3 (30.0%) & 8 (17.8%) & 10 (32.3%) & \\
\textbf{Never} & 6 (60.0%) & 32 (71.1%) & 15 (48.4%) & \\
\hline
\textbf{Aa titer} & 0.58 ± 0.58 & 0.96 ± 0.27 & 1.15 ± 0.33 & 0.6892 \\
\textbf{Pg titer} & 0.23 ± 1.37 & 1.63 ± 0.64 & 1.63 ± 0.78 & 0.4422 \\
\hline
\end{tabular}
\end{table}

\begin{table}[h]
\centering
\begin{tabular}{|l|c|c|c|c|}
\hline
\textbf{DAS28-CRP} & \textbf{Low activity} & \textbf{Moderate activity} & \textbf{High activity} & \textbf{P-value} \\
\hline
\textbf{2.3 ≤ DAS28 < 2.7} (n = 6) & & & & \\
\hline
\textbf{Current} & 0 (0.0%) & 11 (26.8%) & 10 (29.4%) & 0.3316 \textsuperscript{a} (0.2629) \\
\textbf{Former} & 1 (16.7%) & 4 (9.8%) & 7 (20.6%) & \\
\textbf{Never} & 5 (83.3%) & 26 (71.1%) & 15 (48.4%) & \\
\hline
\textbf{Aa titer} & 0.45 ± 0.78 & 0.84 ± 0.30 & 1.44 ± 0.33 & 0.2875 \\
\textbf{Pg titer} & 0.58 ± 1.83 & 1.66 ± 0.70 & 1.47 ± 0.77 & 0.8576 \\
\hline
\end{tabular}
\end{table}

In conclusion, smoking is a novel finding that infection with periodontal pathogenic bacteria seems to interfere with the therapeutic response of RA. Although all RA treatments for the patients in this study were conventional synthesis disease...
modifying anti rheumatic drug (csDMARDs) such as methotrexate or tacrolimus with or without prednisolone, it is essentially necessary to confirm that there is no significant difference in RA treatment regimen between the comparators. There may also be the influence of other factors such as differences in genetic background like SE and individual differences in humoral immune response. In contrast, we did not find a clear difference in the therapeutic response due to smoking in this study (Fig. 2). It has been reported that there is no difference in the mean DAS28 score at 48 and 102 weeks based on smoking status (p = 0.881)\textsuperscript{52}, while non-smokers have a higher EULAR response rate than smokers or those with a history of smoking\textsuperscript{53}.

![Figure 2. Relationship between therapeutic response and smoking. Shown in the Marimekko Chart (A,B) EULAR response criteria; (C,D) DAS ratio response criteria; (A,C) DAS28-ESR; (B,D) DAS28-CRP. Open bar represents never smoking; shaded bar represents former smoking; closed bar represents current smoking. Good responders had little smoking experience; however, there was no significant difference between groups (P-value: Pearson's chi-square test). CRP C-reactive protein, DAS disease activity score, ESR erythrocyte sedimentation rate, EULAR European Alliance of Associations for Rheumatology.](image-url)
This study had three major limitations. First, serum IgG antibody titers were measured only in the sera obtained before RA treatment. Second, the oral conditions of the target patients were not clear. Therefore, it is necessary that serum IgG antibody titers after RA treatment and fluctuations in APCA levels and disease activity after periodontal treatment are clarified in future studies. For example, Zhao et al.54 reported that patients with
RA and periodontitis had significantly higher levels of CRP, ACPA, ESR, and DAS28 than those with RA without periodontitis. They suggested that nonsurgical periodontal treatment is effective in improving the clinical outcome of RA, and the routine use of this therapy is strongly recommended for patients with RA and periodontitis. Furthermore, nonsurgical periodontal therapy may aid in the control of RA-related autoimmune markers, such as serum ACPA in patients with chronic periodontitis.66 However, controlled clinical trials have been reported in systematic reviews and open-label randomized controlled trials.67–69 Thus, in third, randomized controlled trials and large-scale observational studies investigating the effect of periodontal bacterial infection on RA treatment response are needed in future. Although there are these limitations, it is our interests whether the therapeutic response can be predicted by the evaluation of infection of periodontal pathogenic bacteria. This is one of the benefits for the rheumatologists and physicians to screen the infection of periodontal pathogenic bacteria using blood test without any further dental examinations. This may allow physicians to predict the treatment resistance of RA related to this infection and consult periodontologists for precise examination of periodontitis.

Although we could not find any significant correlation between smoking and clinical features of RA, we found that Pg infection in periodontitis may be involved with the elevated levels of ACPA, and Pg and Aa infections may influence the therapeutic response of RA.

Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author, who has the ORCID identifier 0000-0002-4712-6829, on reasonable request.

Received: 4 January 2022; Accepted: 7 July 2022
Published online: 19 July 2022

References
1. Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet 388, 2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-4 (2016).
2. Potempa, J., Mydel, P. & Koziel, J. The case for periodontitis in the pathogenesis of rheumatic arthritis. Nat. Rev. Rheumatol. 13, 606–620. https://doi.org/10.1038/nrrheum.2017.132 (2017).
3. de Molón, R. S., Rossa, C. Jr., Thurlings, R. M., Cirelli, J. A. & Koenders, M. I. Linkage of periodontitis and rheumatoid arthritis: Current evidence and potential biological interactions. Int. J. Mol. Sci. 20, 4541. https://doi.org/10.3390/ijms20184541 (2019).
4. Mikuls, T. R. et al. Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheum. 66, 1090–1100. https://doi.org/10.1002/art.38348 (2014).
5. Hashimoto, H., Hashimoto, S., Muto, A., Dewake, N. & Shimazaki, Y. Influence of plaque control on the relationship between rheumatoid arthritis and periodontal health status among Japanese rheumatoid arthritis patients. J. Periodontol. 89, 1033–1042. https://doi.org/10.1002/PER7.017-0575 (2018).
6. Demmer, R. T., Molitor, J. A., Jacobs, D. R. Jr. & Michalowicz, B. S. Periodontal disease, tooth loss and incident rheumatoid arthritis: results from the first national health and nutrition examination survey and its epidemiological follow-up study. J. Clin. Periodontol. 38, 998–1006. https://doi.org/10.1111/j.1600-051X.2011.01776.x (2011).
7. Scher, J. U. et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum. 64, 3083–3094. https://doi.org/10.1002/art.34359 (2012).
8. Weis, S., Beltran, V., Chaparro, A., Espinosa, F. & Riedemann, J. P. Association between chronic periodontitis and rheumatoid arthritis: A systematic review. Rev. Med. Clin. 147, 762–775. https://doi.org/10.4067/S0034-98772019000600762 (2019).
9. Fuggle, N. R., Smith, T. O., Kaul, A. & Sofat, N. Hand to mouth: A systematic review and meta-analysis of the association between rheumatoid arthritis and periodontal disease. Front. Immunol. 7, 80. https://doi.org/10.3389/fimmu.2016.00080 (2016).
10. Lamster, I. B., Kalushnner-Shapira, J., Herrera-Abreu, M., Sinha, R. & Grbic, J. T. Serum IgG antibody response to Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis: Implications for periodontal diagnosis. J. Clin. Periodontol. 25, 510–516. https://doi.org/10.1038/1600-051X.1998.02480.x (1998).
11. Dye, B. A. et al. Serum antibodies to periodontal bacteria as diagnostic markers of periodontitis. J. Periodontol. 80, 634–647. https://doi.org/10.1902/jop.2009.080474 (2009).
12. McGrath, W. T., Potempa, J., Farley, D. & Travis, J. Purification, characterization, and sequence analysis of a potential virulence factor from Porphyromonas gingivalis, peptidylarginine deiminase. Infect. Immun. 67, 3248–3256. https://doi.org/10.1128/IAI.67.7.3248-3256.1999 (1999).
13. Lundberg, K., Wegner, N., Yucel-Lindberg, T. & Venables, P. J. Periodontitis in RA: the citrullinated enolase connection. Nat. Rev. Rheumatol. 6, 727–730. https://doi.org/10.1038/rrheum.2010.139 (2010).
14. Sakaguchi, W. et al. Detection of anti-citrullinated protein antibody (ACPAs) in saliva for rheumatoid arthritis using DBA mice infected with Porphyromonas gingivalis. Arch. Oral. Biol. 108, 104510. https://doi.org/10.1016/j.archoralbio.2019.104510 (2019).
15. Okada, M. et al. Antibody responses to periodontopathic bacteria in relation to rheumatoid arthritis in Japanese adults. J. Periodontol. 82, 1433–1441. https://doi.org/10.1902/jop.2011.110020 (2011).
16. Arvikar, S. L. et al. Clinical correlations with Porphyromonas gingivalis antibody responses in patients with early rheumatoid arthritis. Arthritis Res Ther. 15, R109. https://doi.org/10.1186/ar4289 (2013).
17. Kobayashi, T. et al. Serum immunoglobulin G levels to Porphyromonas gingivalis peptidylarginine deiminase affect clinical response to biological disease-modifying antirheumatic drug in rheumatoid arthritis. PLoS ONE 11, e0154182. https://doi.org/10.1371/journal.pone.0154182 (2016).
18. Konig, M. E. et al. Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. Sci. Transl. Med. 8, 369ra176. https://doi.org/10.1126/scitranslmed.aad1921 (2016).
19. Schürmacher, J. et al. Cross-sectional evaluation of periodontal status and microbiologic and rheumatoid parameters in a large cohort of patients with rheumatoid arthritis. J. Periodontol. 88, 368–369. https://doi.org/10.1902/jop.2016.160355 (2017).
20. Mikuls, T. R. et al. The subgingival microbiome in patients with established rheumatoid arthritis. Rheumatology 57, 1162–1172. https://doi.org/10.1093/rheumatology/key052 (2018).
21. Seldin, M. F., Amos, C. I., Ward, R., & Gregersen, P. K. The genetics revolution and the assault on rheumatoid arthritis. Arthritis Rheum. 42, 1071–1079. https://doi.org/10.1002/1529-0131.C24-8 (1999).
22. Gregersen, P. K., Silver, J. & Winchester, R. I. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30, 1205–1213. https://doi.org/10.1002/art.1780301102 (1987).
23. vanGaalen, F. A. et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum. 50, 2113–2121. https://doi.org/10.1002/art.20316 (2004).
Acknowledgements
We would like to thank our medical staff for supporting the immune serum examination and for having useful discussions. We would also like to thank Yumi Koumori for her timely help in preparing the large number of samples and the detailed clinical data of patients.

Author contributions
K.T.-H., Y.K. and S.T. constructed the study design. Y.K. collected samples of patients with RA or PMR. K.T.-H., K.O., K.S., T.Y. and S.T. performed the immune serum examination for periodontal disease, and analyzed the patient data with Y.K. K.T.-H. was a major contributor in writing the manuscript, and Y.K., T.Y. and S.T. did the brush up. All authors read and approved the final manuscript.

Funding
This work was supported in part by the Grant-in-Aid for Scientific Research C (20K09954) to KT-H from the Japan Society for the Promotion of Science (JSPS), Japan.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-16279-z.

Correspondence and requests for materials should be addressed to S.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022